These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11457560)

  • 1. A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers.
    Toledo H; Baly A; Castro O; Resik S; Laferté J; Rolo F; Navea L; Lobaina L; Cruz O; Míguez J; Serrano T; Sierra B; Pérez L; Ricardo ME; Dubed M; Lubián AL; Blanco M; Millán JC; Ortega A; Iglesias E; Pentón E; Martín Z; Pérez J; Díaz M; Duarte CA
    Vaccine; 2001 Jul; 19(30):4328-36. PubMed ID: 11457560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The multi-epitope polypeptide approach in HIV-1 vaccine development.
    Cano CA
    Genet Anal; 1999 Nov; 15(3-5):149-53. PubMed ID: 10596755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prime-boost regime that combines Montanide ISA720 and Alhydrogel to induce antibodies against the HIV-1 derived multiepitope polypeptide TAB9.
    Raya NE; Quintana D; Carrazana Y; Gómez CE; Duarte CA
    Vaccine; 1999 Jun; 17(20-21):2646-50. PubMed ID: 10418914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The V3 loop based multi-epitope polypeptide TAB9 adjuvated with montanide ISA720 is highly immunogenic in nonhuman primates and induces neutralizing antibodies against five HIV-1 isolates.
    Gómez CE; Navea L; Lobaina L; Dubed M; Expósito N; Soto A; Duarte CA
    Vaccine; 1999 May; 17(18):2311-9. PubMed ID: 10403600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.
    Keefer MC; Graham BS; McElrath MJ; Matthews TJ; Stablein DM; Corey L; Wright PF; Lawrence D; Fast PE; Weinhold K; Hsieh RH; Chernoff D; Dekker C; Dolin R
    AIDS Res Hum Retroviruses; 1996 May; 12(8):683-93. PubMed ID: 8744579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial.
    Oliveira GA; Wetzel K; Calvo-Calle JM; Nussenzweig R; Schmidt A; Birkett A; Dubovsky F; Tierney E; Gleiter CH; Boehmer G; Luty AJ; Ramharter M; Thornton GB; Kremsner PG; Nardin EH
    Infect Immun; 2005 Jun; 73(6):3587-97. PubMed ID: 15908388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of epitope permutations in the antibody response of mice to a multi-epitope polypeptide of the V3 loop of human immunodeficiency virus type 1.
    Aguilar A; Carrazana Y; Duarte CA
    Biomol Eng; 2001 Oct; 18(3):117-24. PubMed ID: 11566603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.
    Roestenberg M; Remarque E; de Jonge E; Hermsen R; Blythman H; Leroy O; Imoukhuede E; Jepsen S; Ofori-Anyinam O; Faber B; Kocken CH; Arnold M; Walraven V; Teelen K; Roeffen W; de Mast Q; Ballou WR; Cohen J; Dubois MC; Ascarateil S; van der Ven A; Thomas A; Sauerwein R
    PLoS One; 2008; 3(12):e3960. PubMed ID: 19093004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neutralizing antibodies to 5 HIV-1 strains in macaques immunized with the multi-epitope polypeptide TAB9].
    Navea Leyva LM; Lobaina Bartelemy L; Dubed Echevarría M; Alvarez Seguí G; Gómez Rodríguez C; Duarte Cano C
    Rev Cubana Med Trop; 2000; 52(2):115-8. PubMed ID: 11107905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720.
    Lawrence GW; Saul A; Giddy AJ; Kemp R; Pye D
    Vaccine; 1997 Feb; 15(2):176-8. PubMed ID: 9066035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group.
    Graham BS; Keefer MC; McElrath MJ; Gorse GJ; Schwartz DH; Weinhold K; Matthews TJ; Esterlitz JR; Sinangil F; Fast PE
    Ann Intern Med; 1996 Aug; 125(4):270-9. PubMed ID: 8678389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant.
    Saul A; Lawrence G; Allworth A; Elliott S; Anderson K; Rzepczyk C; Martin LB; Taylor D; Eisen DP; Irving DO; Pye D; Crewther PE; Hodder AN; Murphy VJ; Anders RF
    Vaccine; 2005 Apr; 23(23):3076-83. PubMed ID: 15811655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.
    Keefer MC; Graham BS; Belshe RB; Schwartz D; Corey L; Bolognesi DP; Stablein DM; Montefiori DC; McElrath MJ; Clements ML
    AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1713-23. PubMed ID: 7888231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaques.
    Langermans JA; Schmidt A; Vervenne RA; Birkett AJ; Calvo-Calle JM; Hensmann M; Thornton GB; Dubovsky F; Weiler H; Nardin E; Thomas AW
    Vaccine; 2005 Sep; 23(41):4935-43. PubMed ID: 15998554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity.
    Graham BS; McElrath MJ; Keefer MC; Rybczyk K; Berger D; Weinhold KJ; Ottinger J; Ferarri G; Montefiori DC; Stablein D; Smith C; Ginsberg R; Eldridge J; Duerr A; Fast P; Haynes BF;
    PLoS One; 2010 Aug; 5(8):e11995. PubMed ID: 20706632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51.
    Herrera S; Fernández OL; Vera O; Cárdenas W; Ramírez O; Palacios R; Chen-Mok M; Corradin G; Arévalo-Herrera M
    Am J Trop Med Hyg; 2011 Feb; 84(2 Suppl):12-20. PubMed ID: 21292873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative.
    Bartlett JA; Wasserman SS; Hicks CB; Dodge RT; Weinhold KJ; Tacket CO; Ketter N; Wittek AE; Palker TJ; Haynes BF
    AIDS; 1998 Jul; 12(11):1291-300. PubMed ID: 9708408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant.
    Saul A; Lawrence G; Smillie A; Rzepczyk CM; Reed C; Taylor D; Anderson K; Stowers A; Kemp R; Allworth A; Anders RF; Brown GV; Pye D; Schoofs P; Irving DO; Dyer SL; Woodrow GC; Briggs WR; Reber R; Stürchler D
    Vaccine; 1999 Aug; 17(23-24):3145-59. PubMed ID: 10462251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity comparison of a multi-antigenic peptide bearing V3 sequences of the human immunodeficiency virus type 1 with TAB9 protein in mice.
    Cruz LJ; Quintana D; Iglesias E; Garcia Y; Huerta V; Garay HE; Duarte C; Reyes O
    J Pept Sci; 2000 May; 6(5):217-24. PubMed ID: 10823490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.
    Belshe RB; Graham BS; Keefer MC; Gorse GJ; Wright P; Dolin R; Matthews T; Weinhold K; Bolognesi DP; Sposto R
    JAMA; 1994 Aug; 272(6):475-80. PubMed ID: 7913731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.